Clinical trials offer people with serious and life-threatening diseases a chance to receive investigational medicines that have the potential to improve outcomes. At Genentech, we are deeply committed to addressing barriers to clinical trial participation and advancing inclusive research.
Read our full position statement here.
The genetic data available today does not reflect the majority of our diverse global population. In order for us to deepen our understanding of disease and develop more personalized treatments, we must have more complete information and study a broader population, including underrepresented racial and ethnic minorities.
Clinical and genetic data enriched by including more representative patient populations will enable us to evolve the promise of personalized healthcare to achieve more accurate diagnoses, improve access to therapies, and optimize treatment outcomes for all patients.
Genentech is committed to advancing the following priorities:
At Roche and Genentech, we believe that improving health outcomes for all patients is core to our mission, and we are committed to being industry leaders in delivering improved health outcomes for all.
In the increasingly diverse world around us, the time is now for research and clinical development to ensure greater inclusion of patients across racial and ethnic groups in support of optimizing health outcomes for all patients worldwide.
Because disease outcomes and drug responses can vary across populations, research must include patients who are racially, ethnically, and gender representative of those who experience disease. We are deeply committed to addressing barriers to clinical trial participation, diversifying genetic data for scientific discovery, and increasing access to innovative diagnostic and therapeutic solutions, by advancing inclusive research.
By building trusted partnerships with patients, providers and across the healthcare ecosystem, we can collectively combine scientific advances, new technologies and real-world data to drive scientific innovation and create new standards for inclusive research.
As we strive to deliver more patient benefit, we are passionately addressing healthcare disparities in order to deliver ever more personalized healthcare solutions for all patients.
Patients want change; providers agree—we need to disrupt the status quo.
How the Advancing Inclusive Research® Site Alliance aims to build a new ecosystem for clinical trial diversity.
Let’s work together to place diversity and inclusion at the forefront of COVID-19 research.